Phenominer Database Results (7 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.56 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 110992 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.67 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 24 days sham surgical group POD17 sham surgical group POD17 110823 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2112.0 % 618.0 2140.81 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 111001 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.41 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 31 days sham surgical group POD24 sham surgical group POD24 110988 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.3 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 110996 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 518.0 % 117.0 405.3 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 111000 3191
BDIX/OrlCrl ratio of proliferating cell nuclear antigen-positive cells to total liver tumorous lesion cells DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 30 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 56.5 % 7.2 24.94 ex vivo light microscopy with immunohistochemistry liver 0.0 37 days sham surgical group POD30 sham surgical group POD30 110819 3191